[Ip-health] Groups to Obama: Peace plan in Colombia threatened to protect corporate patent?

Peter Maybarduk pmaybarduk at citizen.org
Fri May 27 11:05:57 PDT 2016


Read the letter here: 
http://www.citizen.org/documents/letter-community-to-white-house-re-colombia-glivic-pressure.pdf

For Immediate Release:
May 27, 2016

Contact:  Peter Maybarduk, pmaybarduk at citizen.org, (202) 588-7755 
Steve Knievel, sknievel at citizen.org, (202) 588-7769
Don Owens, dowens at citizen.org, (202) 588-7767

Groups Demand Answers from Obama Administration Regarding Alleged U.S. Interference in Colombian Health Measure

Embassy Letters Suggest U.S. Support for Colombia Peace Plan Threatened in Closed-Door Meeting to Protect Big Pharma Profits 

WASHINGTON, D.C. - A coalition of nonprofit groups today demanded answers from the Obama administration about its alleged interference in Colombia's effort to lower the price of a cancer drug. It comes as Colombia moves toward lasting peace after more than 50 years of war and domestic turmoil, and as the country is being considered for hundreds of millions in aid.

Colombia's minister of health, Alejandro Gaviria, appeared at the World Health Assembly this week and spoke of the external pressure his country has faced over a potential compulsory license for imatinib (marketed in Colombia by Novartis under the brand name Glivec), a lifesaving substance used in drugs to treat certain types of leukemia and other cancers of the blood. Compulsory licensing provisions under consideration by the Colombian government would make imatinib available in Colombia for half the current extortionate price and free up scarce health system resources for other lifesaving interventions.

This week 15 members of the U.S. House (http://democrats.waysandmeans.house.gov/sites/democrats.waysandmeans.house.gov/files/documents/Colombia%20Compulsory%20License%20Letter.pdf)  and Senators Brown and Sanders (http://keionline.org/sites/default/files/Senate-Colombian-Compulsory-License-May-26-2016.pdf) expressed serious concern and objected to any efforts to intimidate and discourage Colombia's government from taking measures to protect public health.

"It appears that the U.S. government may have sought to intimidate a country that is trying to protect its people's health. That is unconscionable," said Peter Maybarduk, director of Public Citizen's Access to Medicines Program. "If any member of the U.S. government further implied that U.S. support for peace in Colombia would be in jeopardy, that would represent a terrible new low for American foreign policy."

All countries, including Colombia, have the right to issue compulsory licenses on medicine patents and "the freedom to determine the grounds upon which such licenses are granted," a right confirmed in the World Trade Organization's Doha Declaration.

Colombia's Ministry of Foreign Relations and its Ministry of Health each received letters in late April from their Washington, D.C. embassy describing pressure from U.S. Senate Finance Committee staff and U.S. Trade Representative (USTR). The leaked letters (http://keionline.org/node/2568) expressed concern that Colombian interests in the United States might be at risk if the country issues the compulsory license for imatinib, including U.S. support for Paz Colombia, the Obama administration's signature $450 million aid initiative to support the Colombian peace process.

The coalition of groups, which include the AFL-CIO, Presbyterian Church (USA), Health Global Access Project, Knowledge Ecology International, the Latin America Working Group, Oxfam America, Public Citizen and others sent a letter to Obama today. The letter calls on the administration to clarify publicly that no action taken by Colombia toward expanding access to medicines, and specifically regarding the issuance of a compulsory license on imatinib, will affect U.S. support for the peace process in Colombia.

Imatinib is priced in Colombia at nearly double the country's GDP per capita, and its patent holder Novartis has rejected the Colombian government's offer to negotiate a price reduction for the treatment. High prices for important medicines impose a burden on the public health systems responsible for providing it and lead to the rationing of treatment and other health services.


###
Signatories: 
American Federation of Labor and Congress of Industrial Organizations (AFL-CIO)
BUKO Pharma-Kampagne
Catholics in Alliance for the Common Good
Center for International Policy
Center for Policy Analysis on Trade and Health (CPATH)
Foundation for Integrative AIDS Research (FIAR)
Health Action International
Health Global Access Project (Health GAP)
Institute for Policy Studies, Drug Policy Project
Institute on Race, Equality and Human Rights
Just Foreign Policy
Knowledge Ecology International
Latin America Working Group (LAWG)
LWC Policy Consulting Inc.
Maryknoll Office for Global Concerns
Oxfam America
Pax Christi International
Presbyterian Church (USA)
Public Citizen
Student Global Access Campaign (SGAC)
The Berne Declaration
United Church of Christ, Justice and Witness Ministries
Universities Allied for Essential Medicines (UAEM)
Washington Office on Latin America (WOLA)
Witness for Peace




More information about the Ip-health mailing list